Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
Boehringer Ingelheim
McKinsey
Harvard Business School

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR BELZUTIFAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Belzutifan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02974738 ↗ A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Active, not recruiting Peloton Therapeutics, Inc. Phase 1 2016-12-07 The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
NCT03401788 ↗ A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) Active, not recruiting Peloton Therapeutics, Inc. Phase 2 2018-05-02 This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.
NCT03445169 ↗ A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets Completed Peloton Therapeutics, Inc. Phase 1 2018-02-23 This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of belzutifan Tablets. The study will consist of two periods and will be conducted in a crossover fashion.
NCT03634540 ↗ A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Recruiting Peloton Therapeutics, Inc. Phase 2 2018-09-27 This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Belzutifan

Condition Name

Condition Name for Belzutifan
Intervention Trials
Carcinoma, Renal Cell 7
Renal Cell Carcinoma 3
Clear Cell Renal Cell Carcinoma 3
RCC 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Belzutifan
Intervention Trials
Carcinoma, Renal Cell 13
Carcinoma 13
Neoplasms 2
Kidney Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Belzutifan

Trials by Country

Trials by Country for Belzutifan
Location Trials
United States 115
France 28
Russian Federation 20
Spain 19
Japan 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Belzutifan
Location Trials
Texas 11
Tennessee 9
Michigan 8
New York 7
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Belzutifan

Clinical Trial Phase

Clinical Trial Phase for Belzutifan
Clinical Trial Phase Trials
Phase 3 4
Phase 2 6
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Belzutifan
Clinical Trial Phase Trials
Recruiting 11
Not yet recruiting 5
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Belzutifan

Sponsor Name

Sponsor Name for Belzutifan
Sponsor Trials
Merck Sharp & Dohme Corp. 13
Peloton Therapeutics, Inc. 4
Eisai Inc. 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Belzutifan
Sponsor Trials
Industry 20
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.